Looking for a substitute for Mounjaro? Here is what the evidence shows

The biggest misconception: that any GLP-1 medicine is interchangeable with Mounjaro

A lot of people arrive at this question assuming that GLP-1 medicines are all roughly the same thing with different brand names. It is an understandable shortcut, and it is worth letting go of gently, because the mechanism matters here.

Mounjaro works on two receptors: GIP and GLP-1. Most other weight-loss medicines in this class work on GLP-1 alone. That additional GIP pathway appears to contribute meaningfully to Mounjaro's results. In the SURMOUNT-1 trial, participants on the 15mg dose lost around 20–21% of their body weight on average over 72 weeks. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine, compared tirzepatide directly against semaglutide 2.4mg and found greater average weight reduction with tirzepatide. Those are trial-population averages, not personal predictions, but they reflect a genuine mechanistic difference.

So calling Wegovy or any other medicine a straight substitute misses the point. If you are wondering whether there is a substitute for Mounjaro that replicates its dual-receptor action, the short answer is that nothing currently licensed in the UK works in exactly the same way. Our page on retatrutide versus Mounjaro covers some of the emerging pipeline medicines that may one day change this picture further.

Which licensed UK medicines come closest for weight management?

Currently, the main alternatives within the licensed UK weight-management landscape are semaglutide-based. Wegovy, the injectable form, has been approved by the MHRA for adults with a BMI of 30 or above, or 27 and above with a weight-related condition. The STEP 1 trial (68 weeks) showed average weight reduction of around 15% at the 2.4mg maintenance dose. In January 2026 the MHRA approved a higher 7.2mg dose, and early data at that strength pushed average results closer to Mounjaro territory, around 20.7% over 72 weeks. A single-dose 7.2mg pen followed in April 2026.

The newer option is Wegovy tablets, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK. The tablet schedule runs from 1.5mg up to a 25mg maintenance dose. Trial data (OASIS 4, 64 weeks) showed around 13.6% average weight loss versus placebo, or approximately 17% among participants who stayed fully adherent. That last figure is worth keeping in context: it describes a specific subgroup, not a typical result. The tablet's practical advantage is real, though, no injection, no refrigeration, and a straightforward morning routine.

Orlistat, a lipase inhibitor taken with meals, is also licensed for weight management in the UK and works through a completely different mechanism, reducing the amount of dietary fat absorbed. It is available in prescription and lower-strength pharmacy versions. For a fuller look at how the licensed options compare on cost, our Mounjaro price comparison guide sets out the market context.

What is not a substitute, even though it contains the same active ingredient?

This is where confusion is most common. Ozempic contains semaglutide, exactly as Wegovy does, but its MHRA licence is for type 2 diabetes, not weight management. The same applies to Rybelsus, the oral semaglutide tablet at 3mg, 7mg and 14mg strengths, a diabetes medicine, not a weight-loss one. Prescribing either of those for weight loss falls outside their licensed indications, and a responsible prescriber will not do it on that basis alone.

It follows that anyone offering Ozempic or Rybelsus as a substitute for Mounjaro for weight loss is working outside the approved framework, which is a meaningful clinical and legal distinction rather than a technicality. The NHS medicines page for tirzepatide sets out the licensed purpose clearly, as does the equivalent page for semaglutide. If you are unsure what you have been prescribed or why, that is a conversation worth having with your prescriber rather than making assumptions from the brand name on the box.

There is also the question of medicines sourced outside the licensed UK supply chain. The MHRA has warned repeatedly about counterfeit weight-loss pens sold online and through social media. Any medicine obtained without a prescription and a proper clinical assessment carries risks that go well beyond the question of which drug it contains. Our page on finding a legitimate source for Mounjaro covers the verification steps in detail.

How a prescriber decides which option fits you

The honest answer is that there is no universal best substitute, there is the right medicine for a particular person at a particular point. Prescribers weigh up BMI, existing health conditions, any medicines you already take (contraception and HRT are relevant here, particularly with tirzepatide), previous treatment history, and personal preference around injections versus tablets.

Eligibility also shapes the decision, and our page on the age requirements for Mounjaro explains how that specific criterion is assessed alongside BMI and clinical history. NICE's appraisal of tirzepatide (TA1026) sets out the NHS criteria for Mounjaro, while Wegovy has its own separate recommendation under TA875. Private eligibility follows the licensed indications from the SmPCs rather than NHS commissioning criteria, but a prescriber still assesses everything. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, and individual medical history can affect whether any of these medicines is appropriate at all.

If Mounjaro is unavailable, out of budget, or simply not the right fit on clinical grounds, the conversation about alternatives starts from that full picture. You can read more about the broader licensed treatment landscape on our weight-loss treatment overview, and our clinical team profiles are on the clinical team page if you want to know who reviews consultations. When you are ready to discuss your own situation, the right starting point is a free consultation with our prescribers, who can assess which licensed option, if any, is appropriate for you.